Literature DB >> 27560202

Capecitabine and the Risk of Fingerprint Loss.

Leni van Doorn1, Sebastiaan Veelenturf2, Lisette Binkhorst3, Sander Bins1, Ron Mathijssen1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 27560202     DOI： 10.1001/jamaoncol.2016.2638

Source DB:  PubMed          Journal:  JAMA Oncol        ISSN： 2374-2437            Impact factor:   31.777


× No keyword cloud information.
  5 in total

1.  Fingerprint loss in two patients with Sézary syndrome: clinical and dermatoscopic evaluation.

Authors:  Shamir Geller; Patricia L Myskowski
Journal:  J Dtsch Dermatol Ges       Date:  2020-10-08       Impact factor: 5.584

2.  Capecitabine-Associated Loss of Fingerprints: Report of Capecitabine-Induced Adermatoglyphia in Two Women with Breast Cancer and Review of Acquired Dermatoglyphic Absence in Oncology Patients Treated with Capecitabine.

Authors:  Philip R Cohen
Journal:  Cureus       Date:  2017-01-09

3.  Management of cytotoxic chemotherapy-induced hand-foot syndrome.

Authors:  Johannes J M Kwakman; Yannick S Elshot; Cornelis J A Punt; Miriam Koopman
Journal:  Oncol Rev       Date:  2020-05-13

Review 4.  Loss of Fingerprints as a Side Effect of Capecitabine Therapy: Case Report and Literature Review.

Authors:  Jian Zhao; Xia Zhang; Xiaonan Cui; Di Wang; Bin Zhang; Liying Ban
Journal:  Oncol Res       Date:  2019-09-26       Impact factor: 5.574

5.  Beware the Unexpected Infection: Disseminated Varicella Zoster Virus Mimicking A Drug Eruption.

Authors:  Dina Adimora-Onwuka; Mary Ann Kirkconnell Hall
Journal:  J Investig Med High Impact Case Rep       Date:  2022 Jan-Dec
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.